Aegis talks BL-7040, keeps Buy rating on BioLineRx

BioLineRx (BLRX +5%) is enjoying a strong session (investors seem to like the  BL-7040 update), although the shares are off their premarket highs.

Aegis' Ram Selvaraju says the new data "significantly enhances the level of validation for BL-7040's mechanism of action in IBD."

Buy rating maintained, price target is $7.

Selvaraju is also looking forward to: Results from the Phase 1 trial of BL-8020 and the Phase 2 open-label trial of BL-8040 in the next three to four months, along with top-line Phase 3 data for BL-1040 ... in 2014.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs